Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease
Status:
Recruiting
Trial end date:
2026-07-30
Target enrollment:
Participant gender:
Summary
Branch atheromatous disease (BAD) has been reported to contribute to small-vessel occlusion
and is associated with a higher possibility of early neurological deterioration (END).
Because the pathology of BAD is due to atherosclerosis, the investigators postulate that
early intensive medical treatment with dual antiplatelet therapy(DAPT) and high-intensity
statin may prevent END and recurrent stroke. The investigators hypothesise that intensive
medical therapy can prevent END in BAD using aspirin, clopidogrel and high-intensity statin.